Xgeva gets NICE formal green light
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, has today published final and binding guidance on Amgen's Xgeva (denosumab) for preventing skeletal related events in patients with advanced cancer.